Novel Insights into Molecular Mechanisms and Therapy of Myeloma
A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".
Deadline for manuscript submissions: 5 March 2025 | Viewed by 85
Special Issue Editors
Interests: multiple myeloma; malignant lymphoma; cancer stem cell; epigenetics; drug resistance; autophagy
Special Issue Information
Dear Colleagues,
Multiple myeloma (MM) is a clonal plasma cell malignancy. It is the second most common hematologic malignancy in the United States. Although current anti-myeloma agents, such as immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies, have significantly improved the outcomes of MM patients, MM remains to be an incurable disease with high rates of drug resistance and relapse. A better understanding of the genomic landscape of MM could help clinicians develop more tailored therapy for patients.
Recent advances in genetic and cellular technologies, in combination with diverse treatment approaches, have significantly improved our knowledge on MM.
Collectively, the original research and review articles in this Special Issue cover important aspects of biomedical research. They provide new insights into the molecular mechanisms underlying multiple myeloma and identify novel diagnostic and prognostic biomarkers in various models. This Special Issue focuses on emerging molecular discoveries and approaches, emphasizing the significance of understanding molecular mechanisms in multiple myeloma for the development of novel diagnostic and therapeutic tools.
Prof. Dr. Yusuke Furukawa
Dr. Jian Wu
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- CAR-T therapy
- relapse
- methylation
- drug resistance
- treatment strategy
- molecular mechanism
- novel target
- biomarker
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
